FDA Accepts IND Application for Coya Therapeutics’ COYA 302 for Frontotemporal Dementia
I'm PortAI, I can summarize articles.
Coya Therapeutics Inc. announced that the FDA has accepted its IND application for COYA 302, aimed at treating frontotemporal dementia (FTD). This acceptance allows Coya to proceed with clinical trials for FTD, a condition with significant unmet medical needs and no approved treatments.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments